Outlook Therapeutics, Inc.OTLKNASDAQ
Loading
R&D Expenses Over TimeContracting
Percentile Rank17
3Y CAGR-7.2%
5Y CAGR-11.5%
Year-over-Year Change
Research and development spending
3Y CAGR
-7.2%/yr
vs +2.7%/yr prior
5Y CAGR
-11.5%/yr
Recent acceleration
Acceleration
-9.9pp
Decelerating
Percentile
P17
Within normal range
vs 5Y Ago
0.5x
Contraction
Streak
1 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $21.15M | -100.0% |
| 2025 | $27.18T | +65082964.0% |
| 2024 | $41.76M | +57.9% |
| 2023 | $26.45M | -37.5% |
| 2022 | $42.33M | +8.7% |
| 2021 | $38.96M | +47.9% |
| 2020 | $26.34M | +10.7% |
| 2019 | $23.80M | +28.6% |
| 2018 | $18.50M | -22.3% |
| 2017 | $23.81M | - |